AI Article Synopsis
- The study examines the availability and distribution of rheumatology providers, specifically focusing on internist rheumatologists and their potential to improve care access for children with rheumatic diseases.
- Approximately 50% of children in the U.S. reside within 50 miles of a pediatric rheumatologist, and 90% are near either a pediatric or internist rheumatologist, indicating good overall access.
- The findings reveal that internist rheumatologists are more inclined to treat children if they are practicing in private settings or are located farther from a pediatric specialist, suggesting they play an important role in regions lacking pediatric rheumatologists.
Article Abstract
Objective: To describe rheumatology providers, depict their availability, and determine the extent to which internist rheumatologists may expand access to care for children with rheumatic diseases.
Methods: Using data from the American College of Rheumatology and the Bureau of Health Professions Area Resource File, we generated a national map of providers' practice locations and calculated distances between each county and the nearest rheumatologist. We also performed a logit analysis to identify provider and county characteristics that were associated with internist rheumatologists' willingness to treat children.
Results: Approximately 50% of the under 18 population in the United States live within 50 miles of a pediatric rheumatologist and nearly 90% live within 50 miles of a pediatric rheumatologist or an internist rheumatologist who treats children. Internist rheumatologists in private practice were 3 times as likely as those in medical schools to treat children (P < 0.001). Likewise, internist rheumatologists who live 200 or more miles from a pediatric rheumatologist were more than twice as likely to treat children as those who lived within 10 miles of a pediatric rheumatologist (P < 0.001).
Conclusions: Our analysis suggests that internist rheumatologists are more geographically diffuse than pediatric rheumatologists and act as substitutes for pediatric rheumatologists in those regions that lack such providers. Research is needed to understand the role of internist rheumatologists in caring for children with rheumatic diseases and the quality of the care that they provide to this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.11462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
Rev Med Interne
November 2024
Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France.
Article Synopsis
- The purpose of this project was to update the 2016 recommendations regarding the management of immunosuppressants or biologics in patients with giant cell arteritis (GCA).
- A task force of 18 physicians developed 26 validated recommendations after thorough discussion and a >85% consensus process.
- Key recommendations include using subcutaneous tocilizumab (TCZ) as a first-line treatment when glucocorticoid-sparing is needed, initiating TCZ at diagnosis for patients with specific high-risk conditions, and considering TCZ or methotrexate if glucocorticoid discontinuation is not feasible after 12 months.
Pregnancy Outcomes from a Multidisciplinary Obstetric-Medicine/Rheumatology Clinic in the United States: A Five-Year Retrospective Analysis.
Arthritis Care Res (Hoboken)
December 2024
Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence.
Objective: At Women & Infants Hospital in Providence, Rhode Island, the Specialty Care in Pregnancy clinic combines obstetric-medicine internists with rheumatologists to care for pregnant patients with rheumatologic conditions. These clinics are scarce, with only three known similar clinics in the United States. This study aims to characterize the population cared for in this clinic, identify interventions, and analyze pregnancy outcomes for the birthing parents and newborns.
View Article and Find Full Text PDFInfluence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy.
J Clin Med
July 2024
Internal Medicine and Rheumatology Unit, University Hospital of Parma, 43126 Parma, Italy.
Article Synopsis
- The Janus kinase inhibitors (JAKi) like tofacitinib, baricitinib, upadacitinib, and filgotinib are effective in treating rheumatoid arthritis but faced safety concerns from the FDA and EMA, particularly about serious adverse events (SAEs) such as thrombosis and cancer.
- The study aimed to analyze the impact of the EMA's first two safety warnings on how rheumatologists in Italy prescribed JAKi from July 2019 to June 2022, using data from 29 rheumatology centers.
- Results showed a significant reduction (32%) in JAKi prescriptions after the first warning, with a smaller decrease (16%) observed after the second warning, although there
Renal Manifestations of IgG4-Related Disease: A Concise Review.
Int J Nephrol
June 2024
Queen's University, Kingston, ON, Canada.
Article Synopsis
- IgG4-related disease (IgG4-RD) is a recently identified immune disorder that causes inflammatory masses affecting various organs, making it hard to diagnose and potentially underrecognized.
- Key renal complications include tubulointerstitial nephritis, but other issues like membranous glomerulonephritis, renal masses, and retroperitoneal fibrosis have also been noted.
- The review aims to summarize the history and symptoms of IgG4-RD while focusing on its renal effects, including important aspects like histology, imaging, and treatment to increase awareness among healthcare professionals.
Article Synopsis
- Rheumatoid arthritis (RA) is the most prevalent inflammatory polyarthritis in Bangladesh, prompting the Bangladesh Rheumatology Society (BRS) to develop management recommendations that consider local resources and societal factors.
- A task force of rheumatologists reviewed existing literature and guidelines, formulating a set of 12 recommendations that focus on early diagnosis, disease activity monitoring, and a structured approach to treating RA using various disease-modifying anti-rheumatic drugs (DMARDs).
- The recommendations encompass strategies for starting treatment with methotrexate, adjusting therapy based on patient needs, and emphasizing the importance of screening for infections and vaccinations, aiming to effectively address the high prevalence of RA in the country.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!